|
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. |
|
|
Research Funding - Bluebird Bio (Inst); Kite, a Gilead company (Inst) |
Patents, Royalties, Other Intellectual Property - Bluebird Bio |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Genentech (Inst); Janssen (Inst); Millennium (Inst); Seagen (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |